Yttrium (90Y) tacatuzumab tetraxetan: Difference between revisions
Appearance
Content deleted Content added
Ozzie10aaaa (talk | contribs) m Cleaned up using AutoEd |
|||
Line 12: | Line 12: | ||
| target = [[α-fetoprotein]] |
| target = [[α-fetoprotein]] |
||
<!-- Clinical data --> |
<!-- Clinical data --> |
||
| tradename = |
| tradename = |
||
| pregnancy_AU = |
| pregnancy_AU = |
||
| pregnancy_US = |
| pregnancy_US = |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = |
| legal_AU = |
||
| legal_CA = |
| legal_CA = |
||
| legal_UK = |
| legal_UK = |
||
| legal_US = |
| legal_US = |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
<!-- Pharmacokinetic data --> |
<!-- Pharmacokinetic data --> |
||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
Line 36: | Line 36: | ||
| UNII = GJ2416WK6Y |
| UNII = GJ2416WK6Y |
||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = |
| PubChem = |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
||
<!-- Chemical data --> |
<!-- Chemical data --> |
||
| chemical_formula = C<sub>6470</sub>H<sub>9971</sub>N<sub>1712</sub>O<sub>2007</sub>S<sub>42</sub><sup>90</sup>Y |
| chemical_formula = C<sub>6470</sub>H<sub>9971</sub>N<sub>1712</sub>O<sub>2007</sub>S<sub>42</sub><sup>90</sup>Y |
Revision as of 16:09, 10 February 2023
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | α-fetoprotein |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6470H9971N1712O2007S4290Y |
Molar mass | 145 kg/mol |
|
Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.
References